Peanut allergy treatment market seen reaching $1.4B by 2033

By AI, Created 5:19 PM UTC, May 18, 2026, /AGP/ – The global peanut allergy treatment market is projected to grow from $0.6 billion in 2026 to $1.4 billion by 2033 as diagnosis, awareness and disease-modifying therapies expand. Growth is being driven by rising pediatric peanut allergy rates, while North America leads and Asia Pacific is expected to grow fastest.

Why it matters: - Peanut allergy treatment is shifting from emergency response to longer-term disease management. - The market’s expansion reflects more diagnoses, broader awareness and stronger demand for therapies that can reduce future reactions. - The category now includes treatment options that may improve quality of life beyond carrying injectable epinephrine.

What happened: - The global peanut allergy treatment market is projected to reach US$0.6 billion in 2026 and US$1.4 billion by 2033. - The forecast implies a 11.4% compound annual growth rate during 2026–2033. - The report was published May 13, 2026, from London. - More information is available in the free sample, the customization request page and the full report checkout page.

The details: - Peanut allergy prevalence is rising, especially among children. - Higher diagnosis rates and patient awareness are expanding the treated population. - Traditional care has centered on injectable epinephrine and antihistamines for immediate symptom control. - Oral immunotherapy and epicutaneous therapy are gaining traction as desensitizing treatments. - Biologics that target immune pathways are also reshaping treatment options. - Personalized treatment protocols are becoming more common. - Hospital pharmacies and online pharmacies are expanding patient access and adherence. - The market includes injectable epinephrine and antihistamines by drug type. - Oral and injectable delivery remain the main routes of administration. - Retail pharmacies, hospital pharmacies, online pharmacies and drug stores are key distribution channels.

Between the lines: - The market is moving toward therapies that address the underlying allergy, not just acute symptoms. - That shift favors companies with immunotherapy and biologics pipelines. - Clinical monitoring, safety concerns and strict adherence requirements still limit access in some regions. - Stability and shelf-life issues can raise logistics costs, especially for plant-based or biologically derived formulations. - The competitive landscape is moderately fragmented, which suggests room for both established drugmakers and smaller biotech firms.

What’s next: - North America is projected to hold 37% of the market in 2026. - The U.S. remains a major demand center because of millions of food-allergic individuals. - Europe is expected to grow steadily, supported by clinical guidelines, insurance coverage and epicutaneous treatments such as Viaskin Peanut from DBV Technologies. - Asia Pacific is expected to be the fastest-growing region as diagnostics improve and healthcare access expands. - Teva Pharmaceutical is among the companies working to improve epinephrine availability in the region. - Key players are pursuing pipeline expansion, regulatory approvals and distribution optimization. - Recent activity includes DBV Technologies’ positive Phase 3 VIASKIN trial results, Novartis’ acquisition of Excellergy and Mabylon AG’s Phase I trial of MY006. - U.S. FDA accelerated approval pathways and public awareness campaigns are supporting earlier diagnosis and treatment access.

The bottom line: - Peanut allergy treatment is becoming a growth market built around long-term disease modification, not just emergency care.